Sign Up
Stories
Biopharma Appoints Industry Veteran
Share
Advancements in Cancer Treatment and Mar...
Allergy Diagnostics Market: Rising Preva...
Anima Biotech's Promising Lung Fibrosis ...
4D Molecular Therapeutics Raises $300 Mi...
ANJESO Drug Insight and Market Forecast
Aldeyra Therapeutics R&D Day 2024
Overview
API
Connect Biopharma appoints industry veteran James Huang to its Board of Directors, a significant shareholder of the company. The company is focused on developing therapies for chronic inflammatory diseases, with lead product candidate rademikibart in development for atopic dermatitis and asthma.
Ask a question
How does the development of therapies for atopic dermatitis and asthma contribute to public health?
How might James Huang's appointment impact the strategic direction of Connect Biopharma?
What are the potential implications of the company's focus on chronic inflammatory diseases?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Nov 2023
Dec 2023
Jan 2024
Coverage